Search Within

Department of Medicine

Formats
  1. Journal Article (19622)
  2. Meeting Abstract (16084)
  3. Review (1159)
  4. Book Section (934)
  5. Editorial (612)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (237)
  10. Miscellaneous (91)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22370)
  2. Hematologic Malignancies, Division of (13308)
  3. Center for Hematologic Malignancies (11082)
  4. GSK Faculty (10659)
  5. Survivorship Research (9354)
  6. Division of Subspecialty Medicine (7561)

More Groups

People
  1. Robert Motzer (1251)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1162)
  2. 2024 (2293)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1411)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (904)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2898)
  5. Oxford University Press (2304)
  6. Nature Publishing Group (2122)

More Publishers

Results (39715)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Veno-occlusive disease risk and other outcomes in patients with B-cell precursor acute lymphoblastic leukemia who received inotuzumab ozogamicin and proceeded to hematopoietic stem cell transplantation: A registry-based, observational study
    Meeting Abstract

    Stelljes, M.; de Lima, M.; Kebriaei, P.; Lanza, F.; Cho, C.; Popradi, G.; Zhang, M. J.; Zhang, F.; Welch, V.; Tikka, S.; more...
    Annals of Hematology (2023)

    Fulltext@MSK | Save
  • Final database lock results of the phase 2 cohort of lenvatinib + pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell renal cell carcinoma
    Meeting Abstract

    Lee, C. H.; Shah, A. Y.; Rao, A.; Taylor, M. H.; Pinto, A.; Sarrio, R. G.; Cohn, A. L.; Bilen, M. A.; Ribe, S. G.; Goksel, M.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002
    Meeting Abstract

    Motzer, R. J.; Choueiri, T. K.; Garmezy, B.; O'Neil, B.; Michalski, J.; Barata, P.; Bajaj, A.; Chahoud, J.; Liu, M.; Xu, F.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Functional and translational consequences of immunometabolic coevolution in ccRCC
    Meeting Abstract

    Reznik, E.; Tang, C.; Xie, A.; Liu, E. M.; Kuo, F.; Kim, M.; Golkaram, M.; Chen, Y.; Gupta, S.; Motzer, R.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Genetic basis of relapse after GPRCSD-targeted CAR T cells
    Research Letter

    Mi, X.; Penson, A.; Abdel-Wahab, O.; Mailankody, S.
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save
  • Vemurafenib and obinutuzumab as frontline therapy for hairy cell leukemia
    Journal Article

    Park, J. H.; Devlin, S.; Durham, B. H.; Winer, E. S.; Huntington, S.; von Keudell, G.; Vemuri, S.; Shukla, M.; Falco, V.; Cuello, B.; more...
    NEJM Evidence (2023)

    Fulltext@MSK | Save
  • Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial
    Journal Article

    Rugo, H S.; Bardia, A.; Marmé, F.; Cortés, J.; Schmid, P.; Loirat, D.; Trédan, O.; Ciruelos, E.; Dalenc, F.; Gómez Pardo, P.; more...
    Lancet (2023)

    Fulltext@MSK | Save
  • Tepotinib and capmatinib in patients with MET exon 14 skipping NSCLC: A matching adjusted indirect comparison (MAIC)
    Meeting Abstract

    Pfeiffer, B. M.; Postma, M. J.; Hatswell, A.; Vioix, H.; Paik, P. K.
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Sequencing patterns and treatment effectiveness in ALK-positive aNSCLC following first-line alectinib or brigatinib
    Meeting Abstract

    Preeshagul, I.; Abrahami, D.; Li, B.; Thomaidou, D.; Duncan, K.; Krulewicz, S.; Rupp, M.; Bauman, J.
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Radiotheranostics targeting Delta-like ligand 3 expressing small-cell lung cancers
    Meeting Abstract

    Tendler, S.; Hoang, T.; Bauer, D.; Korsen, J.; Carter, L.; Michel, A.; Degregorio, R.; Pillarsetty, N.; Poirier, J. T.; Lewis, J. S.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save